Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Intermediate-dose anticoagulation plays a critical role in hospital-based patient management, particularly in clinical scenarios requiring controlled and responsive anticoagulant therapy. Unfractionated heparin (UFH) remains widely used due to its rapid onset of action, adjustable dosing, and suitability for monitored clinical environments.
BARIHEP® (Heparin Sodium Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 10000 IU strength is designed to support both preventive and moderate therapeutic anticoagulation, enabling healthcare professionals to manage thromboembolic risks effectively across hospital and specialized care settings — To Share • To Care • To Inspire.
BARIHEP® 10000 IU (Heparin Sodium Injection) is an unfractionated heparin (UFH) used for both prophylactic and therapeutic anticoagulation. It acts by enhancing antithrombin activity, inhibiting thrombin and factor Xa, and reducing clot formation.
This strength is commonly utilized in hospital settings where controlled anticoagulant therapy is required, including patients undergoing surgical procedures, dialysis, or treatment for thromboembolic conditions.
| Specifications Table | |
| Parameter | Details |
| Brand Name | BARIHEP® |
| Generic Name | Heparin Sodium |
| Arabic Name | باريهيب هيبارين صوديوم |
| Category | Anticoagulants |
| Therapeutic Area | Unfractionated Heparin |
| Dosage Form | Injection |
| Strength | 10000 IU |
| Volume | 5 ml |
| Route / Type | Injectable |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Moderate-dose anticoagulation |
| Management of thromboembolic conditions |
| Dialysis anticoagulation |
| Surgical anticoagulant support |
| Hospital-based treatment protocols |
| It is used for both preventive and therapeutic anticoagulation in hospital settings. |
| It provides a higher and more controlled anticoagulant effect suitable for moderate clinical cases. |
| Hospitals, dialysis units, and surgical care environments. |
| By injection under medical supervision. |
| 5000 IU, 10000 IU, 25000 IU |
